Triluminate trial: deep dive into the outcomes
Summary
In this video, members of the PCR Tricuspid Focus Group Nicole Karam and Ralph Stephan von Bardeleben talk with David Adams and Paul Sorajja about the first landmark trial in the field of tricuspid valve disease, Triluminate. Together they discuss the results presented during the ACC.23/WCC scientific sessions.
The PCR Tricuspid Focus Group will hold a dedicated Webinar on April 4th (5:00 pm, CET), discussing the impact of the TRILUMINATE trial results on clinical practice and giving some additional perspectives on how to interpret them – if interested, easily register here:
